Covid-19: US testing 3 drugs to tamp down coronavirus

By: |
October 16, 2020 8:38 PM

The US National Institutes of Health says the study will enroll 2,100 hospitalised adults with moderate to severe COVID-19 in the United States and Latin America. All will get the antiviral drug remdesivir plus one of the three 'immune-modulating drugs' or a placebo.

The drugs are Bristol Myers Squibb's Orencia and Johnson & Johnson's Remicade, which are sold now for rheumatoid arthritis and an experimental drug from AbbVie called cenicriviroc. (Representational)

 

US government officials are launching a new study testing three drugs to tamp down an overactive response by the immune system that can cause severe illness or death in people with COVID-19.

The US National Institutes of Health says the study will enroll 2,100 hospitalised adults with moderate to severe COVID-19 in the United States and Latin America. All will get the antiviral drug remdesivir plus one of the three ‘immune-modulating drugs’ or a placebo.

The drugs are Bristol Myers Squibb’s Orencia and Johnson & Johnson’s Remicade, which are sold now for rheumatoid arthritis and an experimental drug from AbbVie called cenicriviroc. The drugs work in different ways to inhibit ‘cytokine storm,’ an overproduction of chemicals the body makes to fight infections that can damage lungs, kidneys, the heart and other organs.

“These are all different ways of slowing down an overactive immune system,” said NIH director Dr Francis Collins.

The new study is the fifth and final one in a series of experiments designed by a private-public partnership that includes dozens of drug companies, nonprofit groups and various U.S. government departments. Other therapies being tested include antibody drugs, anti-inflammatory medicines and plasma from COVID-19 survivors

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for COVID-19
2After Tamil Nadu, Madhya Pradesh announces free Covid-19 vaccine for all
3FSSAI conducting quality test of Khoya across India as festive season begins